PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ATAI vs. IOVA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ATAI and IOVA is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

ATAI vs. IOVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-6.04%
-30.71%
ATAI
IOVA

Key characteristics

Sharpe Ratio

ATAI:

-0.30

IOVA:

-0.37

Sortino Ratio

ATAI:

0.08

IOVA:

-0.09

Omega Ratio

ATAI:

1.01

IOVA:

0.99

Calmar Ratio

ATAI:

-0.27

IOVA:

-0.32

Martin Ratio

ATAI:

-0.63

IOVA:

-0.76

Ulcer Index

ATAI:

40.08%

IOVA:

41.21%

Daily Std Dev

ATAI:

83.01%

IOVA:

83.27%

Max Drawdown

ATAI:

-94.77%

IOVA:

-99.37%

Current Drawdown

ATAI:

-93.01%

IOVA:

-96.38%

Fundamentals

Market Cap

ATAI:

$241.63M

IOVA:

$1.80B

EPS

ATAI:

-$0.80

IOVA:

-$1.48

Total Revenue (TTM)

ATAI:

$313.00K

IOVA:

$90.38M

Gross Profit (TTM)

ATAI:

$148.00K

IOVA:

$1.27M

EBITDA (TTM)

ATAI:

-$104.19M

IOVA:

-$287.93M

Returns By Period

In the year-to-date period, ATAI achieves a 4.51% return, which is significantly higher than IOVA's -22.16% return.


ATAI

YTD

4.51%

1M

5.30%

6M

-6.08%

1Y

-22.78%

5Y*

N/A

10Y*

N/A

IOVA

YTD

-22.16%

1M

-26.25%

6M

-30.69%

1Y

-28.36%

5Y*

-24.82%

10Y*

-4.27%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ATAI vs. IOVA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI
The Risk-Adjusted Performance Rank of ATAI is 3434
Overall Rank
The Sharpe Ratio Rank of ATAI is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of ATAI is 3636
Sortino Ratio Rank
The Omega Ratio Rank of ATAI is 3535
Omega Ratio Rank
The Calmar Ratio Rank of ATAI is 3131
Calmar Ratio Rank
The Martin Ratio Rank of ATAI is 3434
Martin Ratio Rank

IOVA
The Risk-Adjusted Performance Rank of IOVA is 3030
Overall Rank
The Sharpe Ratio Rank of IOVA is 2727
Sharpe Ratio Rank
The Sortino Ratio Rank of IOVA is 3030
Sortino Ratio Rank
The Omega Ratio Rank of IOVA is 3131
Omega Ratio Rank
The Calmar Ratio Rank of IOVA is 2828
Calmar Ratio Rank
The Martin Ratio Rank of IOVA is 3232
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ATAI vs. IOVA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Iovance Biotherapeutics, Inc. (IOVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ATAI, currently valued at -0.30, compared to the broader market-2.000.002.004.00-0.30-0.37
The chart of Sortino ratio for ATAI, currently valued at 0.08, compared to the broader market-4.00-2.000.002.004.000.08-0.09
The chart of Omega ratio for ATAI, currently valued at 1.01, compared to the broader market0.501.001.502.001.010.99
The chart of Calmar ratio for ATAI, currently valued at -0.27, compared to the broader market0.002.004.006.00-0.27-0.39
The chart of Martin ratio for ATAI, currently valued at -0.63, compared to the broader market-10.000.0010.0020.0030.00-0.63-0.76
ATAI
IOVA

The current ATAI Sharpe Ratio is -0.30, which is comparable to the IOVA Sharpe Ratio of -0.37. The chart below compares the historical Sharpe Ratios of ATAI and IOVA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-0.30
-0.37
ATAI
IOVA

Dividends

ATAI vs. IOVA - Dividend Comparison

Neither ATAI nor IOVA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ATAI vs. IOVA - Drawdown Comparison

The maximum ATAI drawdown since its inception was -94.77%, roughly equal to the maximum IOVA drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for ATAI and IOVA. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%AugustSeptemberOctoberNovemberDecember2025
-93.01%
-79.15%
ATAI
IOVA

Volatility

ATAI vs. IOVA - Volatility Comparison

Atai Life Sciences N.V. (ATAI) has a higher volatility of 30.59% compared to Iovance Biotherapeutics, Inc. (IOVA) at 18.70%. This indicates that ATAI's price experiences larger fluctuations and is considered to be riskier than IOVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%AugustSeptemberOctoberNovemberDecember2025
30.59%
18.70%
ATAI
IOVA

Financials

ATAI vs. IOVA - Financials Comparison

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and Iovance Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab